What You Should Know:
– Pfizer Inc. has announced a historic agreement with the Trump Administration that is designed to ensure U.S. patients pay lower prices for their prescription medicines while strengthening America’s role as the global leader in biopharmaceutical innovation.
– The voluntary agreement, made in response to a presidential letter, aims to implement measures that ensure Americans receive drug prices comparable to those available in other developed countries.
Lowering Patient Costs and Expanding Access
As part of the agreement, Pfizer will participate in a direct purchasing platform, TrumpRx.gov, which will allow American patients to purchase medicines from Pfizer at a significant discount.
Key details of the pricing component include:
- Savings: The large majority of Pfizer’s primary care treatments and some select specialty brands will be offered at savings ranging as high as 85% and averaging 50%.
- Global Parity: Pfizer will price newly launched medicines at parity with other key developed markets.
Albert Bourla, Chairman and Chief Executive Officer of Pfizer, stated that the agreement is about “putting all patients first and ensuring America remains the world’s leading engine of medical breakthroughs”. He added that the agreement ends the days when American families alone carried the global burden of paying for innovation.
Accelerating U.S. Investment and Manufacturing
The agreement provides Pfizer with the certainty and stability needed on critical fronts like tariffs and pricing.
- Tariffs and Investment: Pfizer has agreed to a three-year grace period during which its products under a Section 232 investigation will not face tariffs, provided the company invests further in U.S. manufacturing.
- Dedicated U.S. Capital: Pfizer is committed to channeling unprecedented resources with an additional $70B dedicated to U.S. research, development, and capital projects in the next few years. This builds upon the company’s more than $83 billion investment in American biotech innovation from 2018–2024.
